Nicola Mikulcik Ohrner
Corporate Officer/Principal presso FORMYCON AG
Posizioni attive di Nicola Mikulcik Ohrner
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| FORMYCON AG | Corporate Officer/Principal | 01/06/2022 | - |
bioeq GmbH
 bioeq GmbH Pharmaceuticals: MajorHealth Technology bioeq GmbH develops biosimilar drugs. The company was founded in March 2014 and is headquartered in Holzkirchen, Germany. | Amministratore Delegato | - | - |
Bioeq AG
 Bioeq AG Pharmaceuticals: MajorHealth Technology Bioeq AG operates as a biopharmaceutical company, which licenses, develops and commercializes biological successor products. It offers FYB201, an advanced biosimilar program intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases. The company is headquartered in Zug, Switzerland. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Nicola Mikulcik Ohrner
Statistiche
Distribuzione geografica
| Germania | 3 |
| Svizzera | 2 |
Posizioni
| Chief Executive Officer | 1 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FORMYCON AG | Health Technology |
| Aziende private | 2 |
|---|---|
bioeq GmbH
bioeq GmbH Pharmaceuticals: MajorHealth Technology bioeq GmbH develops biosimilar drugs. The company was founded in March 2014 and is headquartered in Holzkirchen, Germany. | Health Technology |
Bioeq AG
Bioeq AG Pharmaceuticals: MajorHealth Technology Bioeq AG operates as a biopharmaceutical company, which licenses, develops and commercializes biological successor products. It offers FYB201, an advanced biosimilar program intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases. The company is headquartered in Zug, Switzerland. | Health Technology |
